Search - tctmd.com

Displaying 961 - 980 of 1058

Presentation TCT 2012

Comparison by Optical Frequency-Domain Imaging of Paclitaxel-Eluting Stents and Everolimus-Eluting Stents Implanted in One Coronary Artery in One Procedure. A 12 Months Follow...

Presenter: Jose M. De la Torre Hernandez, Dae-Hyun Lee, Tamara Garcia Camarero, Piedad Lerena, Gonzalo Martin Gorria, Fermin Sainz Laso, Javier Zueco

January 03, 2012

Presentation TCT 2012

Anti-inflammatory Effect of Arsenic Trioxide Eluting Stents in a porcine coronary model

Presenter: Li Shen, Wei Yang, Feirong Gong, Yizhe Wu, Juying Qian, Aijun Sun, Yunzeng Zou, Junbo Ge

January 03, 2012

Presentation TCT 2012

An All Comers Randomized Trial Comparing Xience Prime and Promus Element Stents. Preliminary Results.

Presenter: Jose M. De la Torre Hernandez, Tamara Garcia Camarero, Piedad Lerena, Dae-Hyun Lee, Fermin Sainz Laso, Virginia Frances Santamaria, Monica Fernandez Menendez, Gonzalo Martin Gorria, Javier Zueco

January 03, 2012

News Daily News

Stenting, Surgery Achieve Good Hemodynamic Outcomes in Native Aortic Coarctation

Jason Kahn

December 04, 2011

News Daily News

Elevated CRP—But Not High Platelet Reactivity—Predictive After DES

December 04, 2011

News Conference News

ROTAXUS: Rotablation Does Not Improve Stenting Results in Calcified Lesions

Yael L. Maxwell

November 30, 2011

News Conference News

COBRA: Postdilation with Cryoplasty Reduces Restenosis in Diabetic SFA Lesions

Jason Kahn

November 30, 2011

News Daily News

Some New-Generation Stents Prone to Longitudinal Distortion

November 29, 2011

News Conference News

TWENTE: Zotarolimus DES Noninferior to Everolimus DES at 1 Year

L.A. McKeown

November 28, 2011

News Conference News

PEPCAD-DES: Drug-Coated Balloon Better Than Uncoated Balloon for DES Restenosis

November 27, 2011

News Conference News

RIBS III: Alternative DES Best Bet for DES In-Stent Restenosis

November 22, 2011

News Conference News

Drug-Eluting Balloons an Option for Patients with BMS Restenosis, High Bleeding Risk

November 17, 2011

News Conference News

‘Judicious Use’ of DES in Low-Risk Patients Could Save Over $200 Million per Year

November 16, 2011

News Industry News

REMEDEE Study Meets Primary Endpoint: OrbusNeich’s Combo™ Dual Therapy Stent Is Non-Inferior to DES

November 13, 2011

News Daily News

DES Associated with Less Downstream Lesion Development than BMS

L.A. McKeown

November 04, 2011

News Daily News

Early Study Shows Pelvic Stenting for Erectile Dysfunction Safe, Feasible

October 21, 2011

News Daily News

DES Shows Slight Edge Over BMS in Patients with Kidney Disease

L.A. McKeown

October 21, 2011

News Daily News

Xience Shows Noninferior Late Loss to Cypher, Similar Hard Outcomes

October 17, 2011

News Industry News

Boston Scientific Begins Clinical Trial Enrollment for OMEGA™ Platinum Chromium Stent System

October 05, 2011

News Daily News

Clinical Variables Added to Syntax Score Increases Predictive Ability

L.A. McKeown

September 30, 2011

Advertisement

Comparison by Optical Frequency-Domain Imaging of Paclitaxel-Eluting Stents and Everolimus-Eluting Stents Implanted in One Coronary Artery in One Procedure. A 12 Months Follow...

Anti-inflammatory Effect of Arsenic Trioxide Eluting Stents in a porcine coronary model

An All Comers Randomized Trial Comparing Xience Prime and Promus Element Stents. Preliminary Results.

Stenting, Surgery Achieve Good Hemodynamic Outcomes in Native Aortic Coarctation

Elevated CRP—But Not High Platelet Reactivity—Predictive After DES

ROTAXUS: Rotablation Does Not Improve Stenting Results in Calcified Lesions

COBRA: Postdilation with Cryoplasty Reduces Restenosis in Diabetic SFA Lesions

Some New-Generation Stents Prone to Longitudinal Distortion

TWENTE: Zotarolimus DES Noninferior to Everolimus DES at 1 Year

PEPCAD-DES: Drug-Coated Balloon Better Than Uncoated Balloon for DES Restenosis

RIBS III: Alternative DES Best Bet for DES In-Stent Restenosis

Drug-Eluting Balloons an Option for Patients with BMS Restenosis, High Bleeding Risk

‘Judicious Use’ of DES in Low-Risk Patients Could Save Over $200 Million per Year

REMEDEE Study Meets Primary Endpoint: OrbusNeich’s Combo™ Dual Therapy Stent Is Non-Inferior to DES

DES Associated with Less Downstream Lesion Development than BMS

Early Study Shows Pelvic Stenting for Erectile Dysfunction Safe, Feasible

DES Shows Slight Edge Over BMS in Patients with Kidney Disease

Xience Shows Noninferior Late Loss to Cypher, Similar Hard Outcomes

Boston Scientific Begins Clinical Trial Enrollment for OMEGA™ Platinum Chromium Stent System

Clinical Variables Added to Syntax Score Increases Predictive Ability

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content